Home LiteratureArticle Details
PMID: 14638809 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

The Siderophore receptor IroN of extraintestinal pathogenic Escherichia coli is a potential vaccine candidate.

Infection and immunity ·Vol. 71 ·No. 12 ·2003-12-00 ·Pages 7164-9

Russo TA, McFadden CD, Carlino-MacDonald UB, Beanan JM, Olson R, Wilding GE

Abstract

It would be medically and economically desirable to prevent the millions of annual extraintestinal infections and the thousands of associated deaths due to Escherichia coli. Outer membrane proteins are potential vaccine candidates for the prevention of these infections. This study tested the hypotheses that the siderophore receptor IroN is antigenic and that an IroN-specific antibody response confers protection in vivo. Subcutaneous immunization with denatured IroN resulted in a significant IroN immunoglobulin G (IgG)-specific response in serum (P < 0.0001) but not a systemic or mucosal IroN-specific IgA response. In a mouse model of ascending urinary tract infection, subcutaneous immunization with denatured IroN conferred significant protection against renal (P = 0.0135 and 0.0095 in two independent experiments), but not bladder, infection. These data, together with the previously demonstrated role of IroN in virulence, its expression in human biologic fluids, and its prevalence among extraintestinal pathogenic E. coli strains, support further studies on the role of IroN as a vaccine candidate.

MeSH Terms
Animals Antibodies, Bacterial/blood Bacterial Vaccines/administration & dosage,immunology Disease Models, Animal Escherichia coli/immunology Escherichia coli Infections/microbiology,prevention & control Escherichia coli Proteins/administration & dosage,immunology,metabolism Humans Immunization Mice Mice, Inbred BALB C Receptors, Cell Surface/administration & dosage,immunology,metabolism Urinary Tract Infections/microbiology,prevention & control
Chemicals
Antibodies, Bacterial Bacterial Vaccines Escherichia coli Proteins IroN protein, E coli Receptors, Cell Surface
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Russo Thomas A
Departmentof Medicine, Witebsky Center for Microbial Pathogenesis, Buffalo, New York 14214, USA. trusso@acsu.buffalo.edu
McFadden Catherine D
Carlino-MacDonald Ulrike B
Beanan Janet M
Olson Ruth
Wilding Gregory E
References (36)
36 references, click to expand
  1. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.
    J Infect Dis. 2000 Feb;181(2):774-8 PMID: 10669375
  2. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial.
    JAMA. 2000 Mar 22-29;283(12):1583-90 PMID: 10735395
  3. Capsular polysaccharide and O-specific antigen divergently modulate pulmonary neutrophil influx in an Escherichia coli model of gram-negative pneumonitis in rats.
    Infect Immun. 2000 May;68(5):2854-62 PMID: 10768982
  4. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN(E. coli), among Escherichia coli isolates from patients with urosepsis.
    Infect Immun. 2000 May;68(5):3040-7 PMID: 10769012
  5. Proposal for a new inclusive designation for extraintestinal pathogenic isolates of Escherichia coli: ExPEC.
    J Infect Dis. 2000 May;181(5):1753-4 PMID: 10823778
  6. Phylogenetic distribution of extraintestinal virulence-associated traits in Escherichia coli.
    J Infect Dis. 2001 Jan 1;183(1):78-88 PMID: 11106538
  7. Increasing rates of hospitalization due to septicemia in the US elderly population, 1986-1997.
    J Infect Dis. 2001 Feb 15;183(4):596-603 PMID: 11170985
  8. Efficacy and safety of recombinant human activated protein C for severe sepsis.
    N Engl J Med. 2001 Mar 8;344(10):699-709 PMID: 11236773
  9. Frequency of isolation of pathogens from bloodstream, nosocomial pneumonia, skin and soft tissue, and urinary tract infections occurring in European patients.
    Eur J Clin Microbiol Infect Dis. 2001 Mar;20(3):188-91 PMID: 11347669
  10. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections.
    Ann Intern Med. 2001 Jul 3;135(1):41-50 PMID: 11434731
  11. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care.
    Crit Care Med. 2001 Jul;29(7):1303-10 PMID: 11445675
  12. Identification of a new iron-regulated virulence gene, ireA, in an extraintestinal pathogenic isolate of Escherichia coli.
    Infect Immun. 2001 Oct;69(10):6209-16 PMID: 11553562
  13. Deaths: preliminary data for 2000.
    Natl Vital Stat Rep. 2001 Oct 9;49(12):1-40 PMID: 11694979
  14. Epidemiological correlates of virulence genotype and phylogenetic background among Escherichia coli blood isolates from adults with diverse-source bacteremia.
    J Infect Dis. 2002 May 15;185(10):1439-47 PMID: 11992279
  15. Molecular epidemiology of 3 putative virulence genes for Escherichia coli urinary tract infection-usp, iha, and iroN(E. coli).
    J Infect Dis. 2002 May 15;185(10):1521-4 PMID: 11992291
  16. Reappraisal of community-acquired bacteremia: a proposal of a new classification for the spectrum of acquisition of bacteremia.
    Clin Infect Dis. 2002 Jun 1;34(11):1431-9 PMID: 12015688
  17. Humoral immune responses to microbial infections in the genital tract.
    Microbes Infect. 2002 May;4(6):667-77 PMID: 12048036
  18. A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants.
    Vaccine. 2002 Jun 7;20(19-20):2431-8 PMID: 12057597
  19. IroN functions as a siderophore receptor and is a urovirulence factor in an extraintestinal pathogenic isolate of Escherichia coli.
    Infect Immun. 2002 Dec;70(12):7156-60 PMID: 12438401
  20. Identification of pathogen-specific and conserved genes expressed in vivo by an avian pathogenic Escherichia coli strain.
    Proc Natl Acad Sci U S A. 2003 Jan 7;100(1):247-52 PMID: 12506201
  21. Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem.
    Microbes Infect. 2003 Apr;5(5):449-56 PMID: 12738001
  22. Gal-Gal pili vaccines prevent pyelonephritis by piliated Escherichia coli in a murine model. Single-component Gal-Gal pili vaccines prevent pyelonephritis by homologous and heterologous piliated E. coli strains.
    J Clin Invest. 1989 Jun;83(6):2102-8 PMID: 2566625
  23. Secretory immune responses in mouse vaginal fluid after pelvic, parenteral or vaginal immunization.
    Immunology. 1990 May;70(1):121-5 PMID: 2354856
  24. Alpha-hemolysin contributes to the pathogenicity of piliated digalactoside-binding Escherichia coli in the kidney: efficacy of an alpha-hemolysin vaccine in preventing renal injury in the BALB/c mouse model of pyelonephritis.
    Infect Immun. 1991 Mar;59(3):1153-61 PMID: 1671776
  25. Generation of isogenic K54 capsule-deficient Escherichia coli strains through TnphoA-mediated gene disruption.
    Mol Microbiol. 1993 Jul;9(2):357-64 PMID: 8412686
  26. The presence of K54 capsular polysaccharide increases the pathogenicity of Escherichia coli in vivo.
    J Infect Dis. 1994 Jan;169(1):112-8 PMID: 8277173
  27. The O4 specific antigen moiety of lipopolysaccharide but not the K54 group 2 capsule is important for urovirulence of an extraintestinal isolate of Escherichia coli.
    Infect Immun. 1996 Jun;64(6):2343-8 PMID: 8675348
  28. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination.
    Science. 1997 Apr 25;276(5312):607-11 PMID: 9110982
  29. Characteristics and prevalence within serogroup O4 of a J96-like clonal group of uropathogenic Escherichia coli O4:H5 containing the class I and class III alleles of papG.
    Infect Immun. 1997 Jun;65(6):2153-9 PMID: 9169745
  30. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women.
    JAMA. 1999 Feb 24;281(8):736-8 PMID: 10052444
  31. Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine.
    Infect Immun. 1999 Oct;67(10):5306-14 PMID: 10496910
  32. Protective capacity of antibodies against Escherichia coli and K antigens.
    Infect Immun. 1977 Aug;17(2):286-9 PMID: 70410
  33. Protection against ascending Escherichia coli pyelonephritis in rats and significance of local immunity.
    Infect Immun. 1978 Apr;20(1):78-81 PMID: 352939
  34. Antibodies to Escherichia coli K and O antigens in protection against acute pyelonephritis.
    Prog Allergy. 1983;33:275-88 PMID: 6187016
  35. Passive immunization with antibodies against iron-regulated outer membrane proteins protects turkeys from Escherichia coli septicemia.
    Infect Immun. 1987 May;55(5):1239-42 PMID: 3552995
  36. Protective effects of murine monoclonal antibodies in experimental septicemia: E. coli antibodies protect against different serotypes of E. coli.
    J Infect Dis. 1989 Apr;159(4):641-7 PMID: 2647860
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
DOI
10.1128/IAI.71.12.7164-7169.2003
Email
trusso@acsu.buffalo.edu
Published
2003-12-00
Pages
7164-9
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC308914
Subset
IM
Grants
NIAID NIH HHS · R01 AI042059 · United States
NHLBI NIH HHS · R01 HL069763 · United States
NIAID NIH HHS · AI 42059 · United States
NHLBI NIH HHS · HL 69763 · United States
External Links
PubMed source DOI: 10.1128/IAI.71.12.7164-7169.2003 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2